HOME >> MEDICINE >> NEWS
Enoxaparin beats unfractionated heparin as adjunct therapy for heart attacks

cardial Infraction. (ExTRACT-TIMI 25) study led by the TIMI Study Group (Boston).

"Based on the results of the ExTRACT-TIMI 25 trial, we believe that a strategy using enoxaparin is now the preferred anticoagulant regimen in heart attack patients who receive clot-busting drugs," said Eugene Braunwald, M.D., M.A.C.C., Distinguished Hersey Professor of Medicine, Harvard Medical School, Chairman, TIMI Study Group, Brigham and Women's Hospital.

Researchers found that enoxaparin reduced the combined risk of death and MI within 30 days by 17 percent. Similarly, enoxaparin reduced the 30-day risk of nonfatal repeat MI by 33 percent, and the 30-day combined risk of death, nonfatal MI, and urgent need to re-establish blood flow to the heart by 19 percent. All of the findings were highly statistically significant.

The trial enrolled 20,506 patients from 674 medical centers in 48 countries. All patients had ST-elevation MI (STEMI), a serious form of heart attack characterized by elevation of the "ST segment" on the electrocardiogram. They were treated with a fibrinolytic, or clot-busting, medication within six hours of first experiencing chest pain, and were then randomly assigned to receive therapy with enoxaparin or unfractionated heparin.

To make sure there was no unintended bias in interpreting the results, the trial used a double-blind, double-dummy design: study participants received both intravenous infusions and twice-daily injections without the physician or the patient knowing which contained the study medication and which was the placebo.

The rates of serious bleeding were lower overall than reported in prior trials. Patients who were treated with the enoxaparin strategy were more likely to experience major bleeding. However, when researchers calculated net clinical benefit, which takes into account both effectiveness and safety, the enoxaparin strategy was, on balance, associated with significantly better outcomes.
'"/>


14-Mar-2006


Page: 1 2 3

Related medicine news :

1. US beats Europe for hypertension treatment
2. For super-obese patients, duodenal switch beats gastric bypass
3. Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder
4. New data demonstrate effectiveness of LAMICTAL (lamotrigine) as adjunctive therapy
5. Chemotherapy with bevacizumab increases risk of blood clots in arteries
6. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
7. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
8. Hormone therapy offers new hope for ovarian cancer patients
9. Borderline personality disorder shows improvements with intensive psychotherapy
10. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
(Date:6/24/2016)... ... ... recruitment firm Slone Partners is pleased to announce the placement of Suzanne ... of North American Capital Sales at HTG Molecular . , In ... commercialization of the HTG EdgeSeq system and associated reagents in North America. , Headquartered ...
(Date:6/24/2016)... ... 24, 2016 , ... Today, MTI-GlobalStem, a provider of optimized ... difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene Editing ... is a complete system for culturing and transfecting human pluripotent stem cells ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016  Guerbet announced today that it has been ... Award . One of 12 suppliers to ... its support of Premier members through exceptional local customer ... commitment to lower costs. ... our outstanding customer service from Premier," says Massimo ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology:
Cached News: